Wells Fargo analyst Stan Berenshteyn lowered the firm’s price target on HealthEquity to $89 from $101 and keeps an Overweight rating on the shares. With three-year Treasury rates now appearing to have decisively reversed their upward advance, Wells Fargo thinks HealthEquity’s valuation multiple will move closer to fintech peers with similar revenue growth profiles, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on HQY:
- HealthEquity price target raised to $72 from $68 at Deutsche Bank
- HealthEquity announces HSA sales outlook
- HealthEquity Announces Record HSA Sales Outlook, Presentation at J.P. Morgan Healthcare Conference
- Sharecare named Top Pick for first half of 2023 at BTIG
- Fly Insider: Willdan Group, Medtronic among weeks’ notable insider transactions